Fort Washington Investment Advisors Inc. OH Acquires 43,746 Shares of Medtronic PLC $MDT

Fort Washington Investment Advisors Inc. OH increased its holdings in Medtronic PLC (NYSE:MDT) by 1.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,605,343 shares of the medical technology company’s stock after purchasing an additional 43,746 shares during the quarter. Medtronic accounts for 1.3% of Fort Washington Investment Advisors Inc. OH’s investment portfolio, making the stock its 15th biggest position. Fort Washington Investment Advisors Inc. OH’s holdings in Medtronic were worth $250,269,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the business. Norges Bank bought a new position in shares of Medtronic during the second quarter valued at about $1,432,698,000. Barclays PLC boosted its holdings in Medtronic by 104.6% during the 3rd quarter. Barclays PLC now owns 6,831,203 shares of the medical technology company’s stock valued at $650,604,000 after acquiring an additional 3,492,192 shares during the period. Schroder Investment Management Group boosted its holdings in Medtronic by 78.3% during the 3rd quarter. Schroder Investment Management Group now owns 7,529,849 shares of the medical technology company’s stock valued at $717,143,000 after acquiring an additional 3,307,211 shares during the period. Guinness Asset Management LTD bought a new position in Medtronic during the 3rd quarter worth approximately $275,556,000. Finally, Wellington Management Group LLP increased its stake in Medtronic by 35.3% in the 3rd quarter. Wellington Management Group LLP now owns 10,189,586 shares of the medical technology company’s stock worth $970,456,000 after purchasing an additional 2,658,981 shares during the period. 82.06% of the stock is owned by institutional investors.

Medtronic Trading Down 0.2%

MDT opened at $87.72 on Friday. The stock has a market cap of $112.62 billion, a PE ratio of 24.43, a PEG ratio of 2.26 and a beta of 0.71. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. The business has a 50 day moving average of $95.99 and a 200-day moving average of $96.52. Medtronic PLC has a 52 week low of $79.55 and a 52 week high of $106.33.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.02. The company had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the prior year, the firm earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities research analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be given a $0.71 dividend. The ex-dividend date of this dividend is Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.2%. Medtronic’s dividend payout ratio is currently 79.11%.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Needham reaffirmed a Buy on MDT with a $120 price target, highlighting confidence in Medtronic’s multi‑year growth story and tuck‑in acquisition strategy, which supports upside expectations. Needham Reiterates Buy
• Positive Sentiment: FDA expanded the indication for the OmniaSecure defibrillation lead to allow placement in the left bundle branch area, broadening use for conduction‑system pacing and potentially increasing adoption in cardiac device procedures. OmniaSecure FDA Approval
• Positive Sentiment: Medtronic expanded its pain portfolio via a distribution agreement with Merit Medical to offer the FDA‑cleared ViaVerte basivertebral nerve ablation system — a minimally invasive, implant‑free option for chronic low‑back pain that can drive incremental sales in pain management. ViaVerte Distribution Deal
• Positive Sentiment: Market commentary reiterates the planned spin‑off of Medtronic’s high‑growth diabetes unit later this year — a strategic move investors view as value‑unlocking by creating a pure‑play diabetes company and a leaner core medtech business. Spin-Off Thesis
• Neutral Sentiment: Analyst coverage and articles (Zacks, TipRanks, others) largely frame recent news as mixed but keep consensus sentiment constructive — analysts expect multi‑year EPS growth despite the recent charge. Analyst Commentary
• Negative Sentiment: Medtronic cut FY‑2026 guidance after taking a charge tied to MiniMed approval and private equity considerations; this near‑term hit to earnings outlook is the primary reason shares are down as investors reassess short‑term profitability. Guidance Cut / MiniMed Charge

Insider Activity

In related news, EVP Harry Skip Kiil sold 52,524 shares of Medtronic stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the transaction, the executive vice president directly owned 32,768 shares of the company’s stock, valued at $3,201,761.28. This trade represents a 61.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.26% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of analysts have recently weighed in on MDT shares. Daiwa Securities Group dropped their price objective on Medtronic from $117.00 to $115.00 and set a “buy” rating for the company in a research note on Friday, February 27th. Needham & Company LLC reissued a “buy” rating and set a $120.00 price target on shares of Medtronic in a research report on Thursday. JPMorgan Chase & Co. cut their price target on shares of Medtronic from $105.00 to $100.00 and set a “neutral” rating on the stock in a report on Wednesday, February 18th. Sanford C. Bernstein boosted their price objective on shares of Medtronic from $111.00 to $112.00 and gave the company an “outperform” rating in a research report on Friday, January 9th. Finally, William Blair upgraded shares of Medtronic from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 6th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $110.74.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).